×
About 14,830 results

ALLMedicine™ Attention Deficit Hyperactivity Disorder Center

Research & Reviews  6,757 results

Differential response to pharmacological intervention in ADHD furthers our understandin...
https://doi.org/10.1080/02643294.2021.1908979
Cognitive Neuropsychology; Grandjean A, Suarez I et. al.

Apr 12th, 2021 - The deficit in "interference control" found in children with Attention Deficit Hyperactivity Disorder (ADHD) could be due to two distinct processes, which are not disentangled in most studies: a larger susceptibility to activating prepotent respon...

Effects of Comorbid Developmental Coordination Disorder and Symptoms of Attention Defic...
https://doi.org/10.1007/s10578-021-01155-0 10.1097/00004583-199907000-00011 10.1542/peds.2008-1770 10.1016/j.neuropsychologia.2015.09.032 10.1136/adc.2005.088054 10.1093/pch/11.8.507 10.3389/fped.2019.00474 10.1016/j.ridd.2011.01.017 10.1249/MSS.0000000000001940 10.1155/2017/2760716 10.1111/j.1469-8749.2009.03520.x 10.1177/000841749806500203 10.1016/j.humov.2013.10.003 10.1016/j.ridd.2011.01.040 10.1016/j.humov.2016.03.004 10.1016/j.jsams.2017.05.007 10.1007/s40279-015-0351-6 10.1111/dmcn.14237 10.1177/0883073809333537 10.1212/WNL.50.4.1087 10.1001/jama.288.14.1740 10.1177/088307389801300904 10.1016/j.humov.2005.10.006 10.1375/twin.12.4.381 10.1016/j.ridd.2014.09.023 10.1097/00004583-200006000-00014 10.1097/00004583-199309000-00024 10.2105/AJPH.2015.302630 10.1016/j.ridd.2013.07.021 10.1111/pcn.12096 10.1001/archpsyc.1983.04390010091012 10.1111/j.1440-1819.2007.01634.x 10.1016/j.ridd.2017.08.003 10.1017/S0012162299000341 10.1111/j.1469-8749.2003.tb00952.x 10.1016/j.ridd.2011.02.009 10.1016/j.ypmed.2006.10.004 10.1139/apnm-2016-0151 10.1186/s12889-015-2582-8 10.1136/bmjopen-2019-029784 10.1249/MSS.0000000000001590 10.1111/j.1469-8749.2011.04171.x 10.1111/j.1469-7610.1989.tb00236.x 10.1080/02640410802334196 10.1123/apaq.21.3.197 10.1007/s00787-019-01311-x 10.1016/S0003-9993(97)90138-6 10.1016/j.pnpbp.2010.01.013 10.1016/j.pscychresns.2015.08.001 10.1007/s00221-015-4243-7 10.1080/87565641.2018.1466888 10.1123/pes.24.3.435 10.1080/02701367.2009.10599592 10.1001/archpedi.159.1.46 10.1542/peds.2006-2697 10.1177/108705470000400302 10.1007/s40474-014-0012-8
Child Psychiatry and Human Development; James ME, King-Dowling S et. al.

Apr 10th, 2021 - Developmental coordination disorder (DCD) is often comorbid with attention-deficit/hyperactivity disorder (ADHD). While children with DCD engage in less moderate-to-vigorous physical activity (MVPA) compared to typically developing (TD) children, ...

Unprovoked Dystonic Reaction in a Child Taking Long-Term Methylphenidate.
https://doi.org/10.1177/0897190021999781
Journal of Pharmacy Practice; Pagliaro A, Mattio B et. al.

Apr 5th, 2021 - In this report, we discuss the case of a 9-year-old male with Attention Deficit Hyperactivity Disorder (ADHD) on long-term methylphenidate and guanfacine who experienced acute orofacial dystonia that resolved immediately with the administration of...

ASRS Questionnaire and Tobacco Use: Not Just a Cigarette. A Screening Study in an Itali...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001583
International Journal of Environmental Research and Publi... Zamboni L, Marchetti P et. al.

Apr 3rd, 2021 - Young adults exhibit greater sensitivity than adults to nicotine reinforcement, and Attention Deficit Hyperactivity Disorder (ADHD) increases the risk for early-onset smoking. We investigated the correlation between ADHD Self-Report Scale (ASRS) s...

White matter tract signatures of fiber density and morphology in ADHD.
https://doi.org/10.1016/j.cortex.2021.02.015
Cortex; a Journal Devoted to the Study of the Nervous Sys... Fuelscher I, Hyde C et. al.

Mar 30th, 2021 - Previous studies investigating white matter organization in attention deficit hyperactivity disorder (ADHD) have adopted diffusion tensor imaging (DTI). However, attempts to derive pathophysiological models from this research have had limited succ...

see more →

Guidelines  15 results

Systematic review of gut microbiota and attention-deficit hyperactivity disorder (ADHD)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888126/
Annals of General Psychiatry; Sukmajaya AC

Feb 15th, 2021 - Gut–brain axis (GBA) is a system widely studied nowadays, especially in the neuropsychiatry field. It is postulated to correlate with many psychiatric conditions, one of them being attention-deficit hyperactivity disorder (ADHD). ADHD is a disorde...

Comparable emotional dynamics in women with ADHD and borderline personality disorder
https://bpded.biomedcentral.com/articles/10.1186/s40479-021-00144-y
Borderline Personality Disorder and Emotion Dysregulation; Moukhtarian TR

Feb 11th, 2021 - Emotional dysregulation (ED) is a core diagnostic symptom in borderline personality disorder (BPD) and an associated feature of attention-deficit/hyperactivity disorder (ADHD). We aimed to investigate differences in dynamical indices of ED in dail...

Adult attention deficit hyperactivity disorder in patients with fibromyalgia syndrome: Assessment and disabilities
https://pubmed.ncbi.nlm.nih.gov/33127072/
Journal of Psychiatric Research; Stefano P

Oct 23rd, 2020 - In the broader list of cognitive concerns, neuropsychological testing has shown that attentional impairment may have a specific burden in Fibromyalgia Syndrome (FMS).

Adhansia XR Approved for the Treatment of Pediatric, Adult ADHD
https://www.empr.com/home/news/adhansia-xr-approved-for-the-treatment-of-pediatric-adult-adhd/

Feb 28th, 2019 - The Food and Drug Administration (FDA) has approved Adhansia XR (methylphenidate HCl extended-release; Adlon Therapeutics), a central nervous system stimulant, for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 year...

see more →

Drugs  433 results see all →

Clinicaltrials.gov  7,399 results

Differential response to pharmacological intervention in ADHD furthers our understandin...
https://doi.org/10.1080/02643294.2021.1908979
Cognitive Neuropsychology; Grandjean A, Suarez I et. al.

Apr 12th, 2021 - The deficit in "interference control" found in children with Attention Deficit Hyperactivity Disorder (ADHD) could be due to two distinct processes, which are not disentangled in most studies: a larger susceptibility to activating prepotent respon...

Qelbree - viloxazine hydrochloride capsule, extended release-Supernus Pharmaceuticals, Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a

Apr 11th, 2021 - Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperac...

Effects of Comorbid Developmental Coordination Disorder and Symptoms of Attention Defic...
https://doi.org/10.1007/s10578-021-01155-0 10.1097/00004583-199907000-00011 10.1542/peds.2008-1770 10.1016/j.neuropsychologia.2015.09.032 10.1136/adc.2005.088054 10.1093/pch/11.8.507 10.3389/fped.2019.00474 10.1016/j.ridd.2011.01.017 10.1249/MSS.0000000000001940 10.1155/2017/2760716 10.1111/j.1469-8749.2009.03520.x 10.1177/000841749806500203 10.1016/j.humov.2013.10.003 10.1016/j.ridd.2011.01.040 10.1016/j.humov.2016.03.004 10.1016/j.jsams.2017.05.007 10.1007/s40279-015-0351-6 10.1111/dmcn.14237 10.1177/0883073809333537 10.1212/WNL.50.4.1087 10.1001/jama.288.14.1740 10.1177/088307389801300904 10.1016/j.humov.2005.10.006 10.1375/twin.12.4.381 10.1016/j.ridd.2014.09.023 10.1097/00004583-200006000-00014 10.1097/00004583-199309000-00024 10.2105/AJPH.2015.302630 10.1016/j.ridd.2013.07.021 10.1111/pcn.12096 10.1001/archpsyc.1983.04390010091012 10.1111/j.1440-1819.2007.01634.x 10.1016/j.ridd.2017.08.003 10.1017/S0012162299000341 10.1111/j.1469-8749.2003.tb00952.x 10.1016/j.ridd.2011.02.009 10.1016/j.ypmed.2006.10.004 10.1139/apnm-2016-0151 10.1186/s12889-015-2582-8 10.1136/bmjopen-2019-029784 10.1249/MSS.0000000000001590 10.1111/j.1469-8749.2011.04171.x 10.1111/j.1469-7610.1989.tb00236.x 10.1080/02640410802334196 10.1123/apaq.21.3.197 10.1007/s00787-019-01311-x 10.1016/S0003-9993(97)90138-6 10.1016/j.pnpbp.2010.01.013 10.1016/j.pscychresns.2015.08.001 10.1007/s00221-015-4243-7 10.1080/87565641.2018.1466888 10.1123/pes.24.3.435 10.1080/02701367.2009.10599592 10.1001/archpedi.159.1.46 10.1542/peds.2006-2697 10.1177/108705470000400302 10.1007/s40474-014-0012-8
Child Psychiatry and Human Development; James ME, King-Dowling S et. al.

Apr 10th, 2021 - Developmental coordination disorder (DCD) is often comorbid with attention-deficit/hyperactivity disorder (ADHD). While children with DCD engage in less moderate-to-vigorous physical activity (MVPA) compared to typically developing (TD) children, ...

Unprovoked Dystonic Reaction in a Child Taking Long-Term Methylphenidate.
https://doi.org/10.1177/0897190021999781
Journal of Pharmacy Practice; Pagliaro A, Mattio B et. al.

Apr 5th, 2021 - In this report, we discuss the case of a 9-year-old male with Attention Deficit Hyperactivity Disorder (ADHD) on long-term methylphenidate and guanfacine who experienced acute orofacial dystonia that resolved immediately with the administration of...

FDA Clears Nonstimulant for ADHD in Kids 6 Years and Up
https://www.medscape.com/viewarticle/948727

Apr 4th, 2021 - The US Food and Drug Administration (FDA) has approved the nonstimulant medication viloxazine extended-release capsules (Qelbree, Supernus Pharmaceuticals) for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to ...

see more →

News  221 results

FDA Clears Nonstimulant for ADHD in Kids 6 Years and Up
https://www.medscape.com/viewarticle/948727

Apr 4th, 2021 - The US Food and Drug Administration (FDA) has approved the nonstimulant medication viloxazine extended-release capsules (Qelbree, Supernus Pharmaceuticals) for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to ...

FDA OKs Novel Dual-Action Stimulant Med for ADHD
https://www.medscape.com/viewarticle/947075

Mar 7th, 2021 - The US Food and Drug Administration (FDA) has approved a new, once-daily oral stimulant medication for treatment of attention deficit hyperactivity disorder (ADHD) in people aged 6 years and older. Azstarys (KemPharm, Inc) combines extended-releas...

Systematic review of gut microbiota and attention-deficit hyperactivity disorder (ADHD)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888126/
Annals of General Psychiatry; Sukmajaya AC

Feb 15th, 2021 - Gut–brain axis (GBA) is a system widely studied nowadays, especially in the neuropsychiatry field. It is postulated to correlate with many psychiatric conditions, one of them being attention-deficit hyperactivity disorder (ADHD). ADHD is a disorde...

Strep A and Tic Worsening: Final Word?
https://www.medscape.com/viewarticle/945720

Feb 11th, 2021 - Exposure to Group A streptococcus (GAS) does not appear to worsen symptoms of Tourette syndrome and other chronic tic disorders (CTDs) in children and adolescents, new research suggests. Investigators studied over 700 children and teenagers with C...

Comparable emotional dynamics in women with ADHD and borderline personality disorder
https://bpded.biomedcentral.com/articles/10.1186/s40479-021-00144-y
Borderline Personality Disorder and Emotion Dysregulation; Moukhtarian TR

Feb 11th, 2021 - Emotional dysregulation (ED) is a core diagnostic symptom in borderline personality disorder (BPD) and an associated feature of attention-deficit/hyperactivity disorder (ADHD). We aimed to investigate differences in dynamical indices of ED in dail...

see more →

Patient Education  5 results see all →